GSK Will Re-Do Phase II Wellbutrin Metabolite Studies At Higher Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will need to re-do its Phase II depression program for its metabolite of Wellbutrin (bupropion) after the 60 mg dose failed to meet the primary endpoint